Aelis Farma

France
Buc, Île-de-France, France, 33 077

Company profile

Aelis Farma company profile

Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

Business identity

Contact email
[email protected]
Phone number
+33 5 57 57 37 70
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
33 077
Country code
FR
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$17.1M
Last funding
Post IPO Equity / $4.9M / 2024-07-31
Last equity funding
Post IPO Equity / $4.9M
Investors
7
Lead investors
1
Founders
5
Articles
46
Exited on
2022-02-16

Founders and investors

Founders

Giovanni MarsicanoPier Vincenzo PiazzaSandy FabreStéphanie MonlezunValérie Scappaticci

Lead investors

National Institute on Drug Abuse (NIDA)

Investors

BpifranceInserm Transfert InitiativeNACONational Institute on Drug Abuse (NIDA)Région Nouvelle-Aquitaine